Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 1 Oct 2011

Guzmán-Fulgencio M, Berenguer J, García-Álvarez M, Micheloud D, C López J, Cosín J, Fernández de Castro I, Catalán P, Miralles P, Resino S

Abstract excerpt

The aim of this study was to evaluate the influence of clinical and epidemiological characteristics of 183 HIV/HCV coinfected patients and HCV clearance after antiviral treatment on serum sFas and sFasL levels. Thirty out of 183 patients underwent HCV antiviral therapy with IFN-α + RBV for a duration of 48 weeks. HCV genotype 1 and homeostasis model assessment for insulin resistance (HOMA-IR) had a significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fas Ligand Protein

Share to fas Receptor

Share to Hepacivirus

Share to Hepatitis C

Share to Interferon-alpha

Share to Ribavirin

Source

Identifiers

PMID: 21442358
DOI: 10.1007/s10096-011-1215-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.PMID 21442358Read ↗

Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.Semantic proximity Read ↗

Polymorphisms rs763110 in FASL is linked to hepatitis C virus infection among high-risk populations.Semantic proximity Read ↗

The importance of sCD40 and sCD40L concentration in patients with chronic HCV infection and HIV co-infection.Semantic proximity Read ↗

Role of the Fas/FasL Pathway in HIV or SIV DiseaseSemantic proximity Read ↗

Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.Semantic proximity Read ↗

IL6 and FAS/FASL gene polymorphisms may be associated with disease progression in HIV-1-positive ethnically mixed patients.Semantic proximity Read ↗

Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate.Semantic proximity Read ↗

High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients.Semantic proximity Read ↗

Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients.Semantic proximity Read ↗

Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients.Semantic proximity Read ↗

Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection.Semantic proximity Read ↗

Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.